Pliant Therapeutics (PLRX) Accumulated Depreciation (2019 - 2020)
Pliant Therapeutics (PLRX) reported Accumulated Depreciation of $3.5 million for Q4 2020, up 59.41% year-over-year from $2.2 million in Q1 2020, and up 10.73% quarter-over-quarter from $3.2 million in Q3 2020.
Pliant Therapeutics (PLRX) Accumulated Depreciation (2019 - 2020) Analysis & Trends
Pliant Therapeutics (PLRX) has 2 years of Accumulated Depreciation data on file, last reported at $3.5 million in Q4 2020.
- Accumulated Depreciation for Q4 2020 came in at $3.5 million, up 59.41% year-over-year; the trailing twelve-month figure through Dec 2020 was $3.5 million (up 59.41% YoY), and the FY2020 annual result was $3.5 million, up 59.41% from the prior year.
- Accumulated Depreciation climbed to $3.5 million in Q4 2020 per PLRX's latest filing, from $3.2 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $3.5 million in Q4 2020 and troughed at $2.2 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Pliant Therapeutics | 71.07 Mn | 71.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 3.49 Mn |
| Sep 30, 2020 | 3.15 Mn |
| Jun 30, 2020 | 2.82 Mn |
| Dec 31, 2019 | 2.19 Mn |